NASDAQ:VNDA

Vanda Pharmaceuticals Stock News

Healthcare > Biotechnology

Buy VNDA

*Your capital is at risk

$5.10

-0.0800 (-1.54%)

At Close: Jul 31, 2026

Vanda: Next Phase Of Fanapt Growth Might Be With Bysanti Advancement

03:21pm, Friday, 29'th Aug 2025

Vanda Pharma's revenue growth is driven by Fanapt's label expansion to bipolar I disorder, offsetting declines in HETLIOZ and PONVORY sales. Upcoming catalysts include Bysanti's PDUFA date for bipolar

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences

05:23pm, Thursday, 28'th Aug 2025

WASHINGTON , Aug. 28, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in Septemb

Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

07:00am, Thursday, 28'th Aug 2025

WASHINGTON , Aug. 28, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-184

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

04:40pm, Thursday, 21'st Aug 2025

WASHINGTON, Aug. 21, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has asked Martin Makary, the Commissioner of the U.S. Food and Drug Administration (

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

07:00am, Monday, 18'th Aug 2025

WASHINGTON , Aug. 18, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it secured a landmark victory over the U.S. Food and Drug Administration (FDA) in its

Vanda (VNDA) Q2 Revenue Rises 4%

04:18am, Friday, 01'st Aug 2025

Vanda Pharmaceuticals (VNDA -8.78%), a pharmaceutical company focused on central nervous system and rare disease treatments, reported financial results for Q2 2025 on July 31, 2025. The most important

Vanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call Transcript

04:45pm, Thursday, 31'st Jul 2025

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q2 2025 Earnings Call July 31, 2025 8:00 AM ET Company Participants Kevin Patrick Moran - Senior VP, CFO & Treasurer Mihael H. Polymeropoulos - Founder, Presi

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates

09:40am, Thursday, 31'st Jul 2025

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.08 per share a year ago.

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

07:30am, Thursday, 31'st Jul 2025

Fanapt® Q2 2025 net product sales increased by 27% to $29.3 million compared to Q2 2024 Bysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target acti

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

04:45pm, Wednesday, 23'rd Jul 2025

Conference Call and Webcast to Follow WASHINGTON , July 23, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2025 o

Risks of a blockade in the Strait of Hormuz 'remain absolutely minimalistic': Vanda Insights

10:35pm, Monday, 23'rd Jun 2025

Vandana Hari of Vanda Insights discusses oil price reaction to the U.S. strikes on Iran's nuclear facilities, as well as the likelihood of a potential closure in the Strait of Hormuz.

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

08:00am, Tuesday, 10'th Jun 2025

WASHINGTON , June 10, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the first dose in the first-in-human clinical trial to evaluate the safety and tolerabi

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by